Company Overview

Standard BioTools Inc. is a health‑care enterprise headquartered in South San Francisco, United States. The company operates within the Life Sciences Tools & Services sector and specializes in the development and provision of proprietary mass cytometry and microfluidics technologies. Its mission is to deliver reliable and repeatable insights into health and disease, thereby facilitating the translation of scientific discoveries into improved patient outcomes.

The company was listed on the Nasdaq stock exchange following its initial public offering on February 10, 2011. Its shares are denominated in U.S. dollars and as of April 30, 2026, the closing price stood at $0.94. Over the past 12 months the stock has traded between a low of $0.87 (April 13, 2026) and a high of $1.72 (December 21, 2025). The market capitalization is approximately $363 million. The price‑to‑earnings ratio is negative, at –6.08, reflecting the company’s current earnings profile.

Business Focus

Standard BioTools’ core products include:

  • Mass cytometry instruments that enable high‑throughput, single‑cell analysis of protein expression, offering researchers enhanced resolution for complex biological systems.
  • Microfluidic devices designed for precise manipulation of fluids at the microscale, supporting a range of applications from diagnostics to basic research.

These technologies are intended for use in academic, industrial, and clinical research settings, positioning the company to serve a growing market for advanced life‑sciences instrumentation.

Financial Snapshot

  • Exchange: Nasdaq
  • Currency: USD
  • Market Cap: $363 million
  • 52‑Week Range: $0.87 – $1.72
  • Current Close (30 Apr 2026): $0.94
  • P/E Ratio: –6.08

The negative P/E ratio indicates that Standard BioTools is currently operating at a loss, a common scenario for companies investing heavily in research and development within the life‑sciences tools sector.

Strategic Position

The company’s emphasis on repeatable, high‑resolution analytical tools aligns with the broader industry trend toward precision medicine and single‑cell research. By leveraging its proprietary technologies, Standard BioTools aims to capture market share from established competitors in the cytometry and microfluidics space, while also exploring partnerships and collaborations that could accelerate product adoption.

This article summarizes publicly available information about Standard BioTools Inc. and does not constitute investment advice.